CIMIZT Tablet Ref.[10435] Active ingredients: 17 alpha-Ethinylestradiol Desogestrel

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2020  Publisher: Morningside Healthcare Ltd., Unit C, Harcourt Way, Leicester, LE19 1WP, United Kingdom

Product name and form

Cimizt 150 microgram/30 microgram Tablets.

Pharmaceutical Form

Tablet.

Each tablet is round, white to off-white, 5.00 mm, uncoated, biconvex, debossed with ‘142’ on one side and other side plain.

Qualitative and quantitative composition

Each tablet contains 150 micrograms desogestrel and 30 micrograms ethinylestradiol.

Excipients: 1 uncoated tablet contains 58 mg of lactose anhydrous

For a full list of excipients, see section 6.1.

Active Ingredient Description
17 alpha-Ethinylestradiol

Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.

Desogestrel

Desogestrel is a progestogen. Like other progestogen-only pills, desogestrel is best suited for use during breast feeding and for women who may not or do not want to use oestrogens. In contrast to traditional progestogen-only pills, the contraceptive effect of desogestrel is achieved primarily by inhibition of ovulation. Other effects include increased viscosity of the cervical mucus.

List of Excipients

all-rac-alpha-tocopherol
Potato starch
Povidone (E1201)
Stearic acid (E570)
Silica, colloidal anhydrous (E551)
Lactose, anhydrous

Pack sizes and marketing

Clear transparent PVC/PVdC- Aluminium blister of 21 tablets per calender blister strip available in packs containing 1x21, 3x21 or 6x21 tablets. Each blister is packed in trilaminated pouch.

Clear transparent PVC/PVdC- Aluminium blister of 21 tablets per calender blister strip available in packs containing 1x21, 3x21 or 6x21 tablets. Each blister is packed in trilaminated pouch along with 2g molecular sieve.

Not all pack sizes may be marketed.

Marketing authorization holder

Morningside Healthcare Ltd., Unit C, Harcourt Way, Leicester, LE19 1WP, United Kingdom

Marketing authorization dates and numbers

PL 20117/0231

28/05/2012

Drugs

Drug Countries
CIMIZT United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.